This article summarized the latest R&D progress of Isophane Insulin, the Mechanism of Action for Isophane Insulin, and the drug target R&D trends for Isophane Insulin.

NMD Pharma A/S has revealed that the initial patient has received their first dose in a Phase II clinical study of the ClC-1 inhibitor NMD670 in individuals affected by spinal muscular atrophy.

This article summarized the latest R&D progress of Magnesium Salicylate, the Mechanism of Action for Magnesium Salicylate, and the drug target R&D trends for Magnesium Salicylate.

The Renin-Angiotensin System (RAS) is a crucial fluid-regulating system composed of a series of peptide hormones and corresponding enzymes.

This article summarized the latest R&D progress of Miglitol, the Mechanism of Action for Miglitol, and the drug target R&D trends for Miglitol.

Sandoz gains consent from the European Commission for its unique multiple sclerosis biosimilar, Tyruko® (natalizumab) in Europe.

This article summarized the latest R&D progress of Nalidixic Acid, the Mechanism of Action for Nalidixic Acid, and the drug target R&D trends for Nalidixic Acid.

RANKL, or Receptor Activator of Nuclear Factor Kappa-B Ligand, is a crucial protein involved in the regulation of bone metabolism in the human body.

This article summarized the latest R&D progress of Naphazoline Hydrochloride, the Mechanism of Action for Naphazoline Hydrochloride, and the drug target R&D trends for Naphazoline Hydrochloride.

Lantern Pharma Inc. has started Phase 1 clinical trial on its experimental drug, LP-184, for advanced solid tumors. This is part of the company's ongoing clinical drug development.

This article summarized the latest R&D progress of Phenazepam, the Mechanism of Action for Phenazepam, and the drug target R&D trends for Phenazepam.

Pre-exposure prophylaxis (PrEP) is a preventive measure that involves the use of antiretroviral drugs to reduce the risk of HIV infection in individuals who are not infected but are at high risk of exposure.